2026年欧洲肿瘤内科学会年会（ESMO Congress 2026）定于当地时间10月23日至27日在西班牙马德里举办。北京时间9月22日，ESMO官网正式公布本届大会突破性摘要（Late-Breaking Abstract，LBA）标题。【肿瘤资讯】特此汇总整理，带您速览乳腺癌前沿学术亮点。
Proffered paper 1: Breast cancer, early and advanced stage
日期：2026.10.23
地点：Alicante Auditorium - Hall 6
时间：13:30 - 15:00
LBA23 - Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
TALENT研究最终结果：德曲妥珠单抗（T-DXd）联合或不联合阿那曲唑，或与化疗序贯用于HER2低表达、激素受体阳性早期乳腺癌的新辅助治疗研究
讲者：Sara A. Hurvitz (Seattle, United States of America)
LBA13 - Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): a randomized, phase 3 study (HORIZON-Breast06)
瑞康曲妥珠单抗（SHR-A1811）治疗HER2低表达晚期乳腺癌：随机Ⅲ期研究（HORIZON-Breast06）
讲者：樊英 (中国医学科学院肿瘤医院)
LBA24 - Final Analysis of NRG Oncology/NSABP B-42, a Randomized, Double-blinded, Placebo-controlled Trial of Extended Letrozole in Postmenopausal Women with Hormone-receptor Positive Breast Cancer Who Have Completed Previous Adjuvant Therapy with an Aromatase Inhibitor
NRG Oncology/NSABP B-42研究最终分析：在既往已完成芳香化酶抑制剂辅助治疗的激素受体阳性绝经后乳腺癌患者中，评估来曲唑延长治疗的随机、双盲、安慰剂对照试验。
讲者：Eleftherios P. Mamounas (Orlando, United States of America)
LBA25 - Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
瑞波西利联合非甾体类芳香化酶抑制剂辅助治疗HR阳性、HER2阴性早期乳腺癌：NATALEE研究6年总生存及疗效结果
讲者：Dennis J. Slamon (Los Angeles, United States of America)
LBA50 - PANKU-Breast01: Randomized Phase III Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic (LA/M) Hormone Receptor-Positive/HER2-negative (HR+/HER2-) Breast Cancer (BC)
PANKU-Breast01：伦康依隆妥单抗（iza-bren）治疗既往经治、不可切除的局部晚期或转移性HR阳性、HER2阴性乳腺癌的随机Ⅲ期研究
讲者：兰波 (中国医学科学院肿瘤医院)
Proffered paper 2: Breast cancer, early and advanced stage
日期：2026.10.24
主席：Seock-Ah Im (Seoul, Republic of Korea) Sara A. Hurvitz (Seattle, United States of America)
地点：Alicante Auditorium - Hall 6
时间：08:30 - 10:00
LBA51 - Results From KEYNOTE-B49: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (Pembro) vs Placebo (Pbo) Plus Chemotherapy (CT) in Participants (Pts) With HR+/HER2− Advanced Breast Cancer (ABC)
KEYNOTE-B49研究结果：帕博利珠单抗联合化疗对比安慰剂联合化疗治疗HR阳性、HER2阴性晚期乳腺癌的随机、双盲Ⅲ期研究
讲者：Hope S. Rugo (Duarte, United States of America)
LBA14 - A Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for HER-2 Negative and Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (MBC): Overall Survival Results of the CCTG/BCT MA.40/FINER Study (NCT04650581)
氟维司群联合Ipatasertib治疗HER2阴性、雌激素受体（ER）阳性转移性乳腺癌的双盲、安慰剂对照、随机Ⅲ期试验：CCTG/BCT MA.40/FINER研究（NCT04650581）的总生存结果
讲者：Andrew D. Redfern (Perth, Australia)
LBA26 - Short-term preoperative durvalumab for stage I TNBC: first results from the phase II UNLOCK 14 - POP-DURVA trial
度伐利尤单抗用于Ⅰ期三阴性乳腺癌的短期术前治疗：Ⅱ期UNLOCK 14 - POP-DURVA试验的首次结果
讲者：Joana M. Ribeiro (Villejuif, France)
LBA96 - First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Exploratory analysis of pts with brain metastases in TROPION-Breast02
德达博妥单抗（Dato-DXd）对比化疗一线治疗不适合免疫治疗的局部复发不可手术或转移性三阴性乳腺癌：TROPION-Breast02研究中脑转移患者的探索性分析
讲者：Rebecca A. Dent (Singapore, Singapore)
LBA15 - Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
安尼妥单抗联合白蛋白结合型多西他赛治疗HER2阳性晚期乳腺癌：一项随机Ⅲ期研究
讲者：徐兵河 (中国医学科学院肿瘤医院)
Rapid oral: Breast cancer, early stage
日期：2026.10.23
主席：Lilit Harutyunyan (Yerevan, Armenia) Maria Vittoria Dieci (Padova, Italy) Sandra Ximena Franco Millan (Bogota, Colombia)
地点：Alicante Auditorium - Hall 6
时间：16:15 - 17:45
LBA28 - Compression therapy using normal-sized surgical gloves for prevention of paclitaxel-induced peripheral neuropathy in breast cancer: results from the multicenter randomized AIUR trial
使用常规尺寸外科手套进行压迫治疗，预防乳腺癌患者紫杉醇诱导的周围神经病变：多中心随机AIUR试验结果
讲者：Young-Joon Kang (Incheon, Republic of Korea)
Rapid oral 1: Breast cancer, advanced stage
日期：2026.10.24
主席：William J. Gradishar (Chicago, United States of America, IL) Vesna Bjelic-Radisic (Wuppertal, Germany) Géraldine Gebhart (Brussels, Belgium)
地点：Almeria Auditorium - Hall 9
时间：10:15 - 11:45
LBA16 - VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (Study 2)
VIKTORIA-1：Gedatolisib联合氟维司群、加或不加哌柏西利，对比标准治疗用于HR阳性、HER2阴性晚期乳腺癌的随机、开放标签Ⅲ期研究更新结果（研究2）
讲者：Barbara Pistilli (Villejuif, France)
LBA17 - HER2-PET imaging to predict trastuzumab deruxtecan (T-DXd) efficacy in advanced breast cancer: The phase II PREDICT-HER trial
HER2-PET显像预测德曲妥珠单抗（T-DXd）治疗晚期乳腺癌的疗效：Ⅱ期PREDICT-HER试验
讲者：金娟 (复旦大学附属肿瘤医院)
LBA27 - APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) : Results from a randomized phase 3 study
APEX-Breast01：TQB2102对比化疗治疗HER2低表达复发性或转移性乳腺癌的随机Ⅲ期研究结果
讲者：王树森 (中山大学附属肿瘤防治中心)
Rapid oral 2: Breast cancer, advanced stage
日期：2026.10.26
主席：Antonio Llombart Cussac (Valencia, Spain) Pedram Razavi (New York, United States of America) Sherene Loi (Melbourne, Australia)
地点：Alicante Auditorium - Hall 6
时间：10:15 - 11:45
LBA49 - A DESTINY-Breast09 (DB-)09 analysis of trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC) and baseline (BL) brain metastases (BMs)
DESTINY-Breast09研究分析：德曲妥珠单抗（T-DXd）联合帕妥珠单抗，对比紫杉类药物联合曲妥珠单抗及帕妥珠单抗（THP），治疗基线伴脑转移的HER2阳性晚期或转移性乳腺癌
讲者：Cristina Saura Manich (Barcelona, Spain)
排版编辑：肿瘤资讯-slb
苏公网安备32059002004080号
